Clinical responses in patients.

Slides:

Advertisements

Similar presentations

Mammary ductal carcinoma

Advertisements

These are actual cases to –Stimulate your reading –Test your knowledge of the material Look for the sound icon (often in the upper right hand corner.

SQUAMOUS CELL CARCINOMA

Impact of Lymph-Node Metastatic Site in Patients with Thoracic Esophageal Cancer Edited by: Kunisaki C., Makino H., Kimura J., Oshima T., Fujii S., Takagawa.

Surgical principle of Management of Tumors M.A.Kubtan, MD – FRCS 1 st Lecture 1M.A.Kubtan.

Carcinoid tumors. Develop from the argyrophillic Kulchitsky’s cells that are present in the airway mucosa Neuroendocrine tumor categorized Grade I : typical.

62 years old man Main complaint: Back pain at night but not during the day Loss of appettite Weight loss.

2 years later, she noticed multiple cm

 Determining the Nature of a Breast Abnormality  It is a procedure that may be used to determine whether a lump is a cyst (sac containing fluid) or a.

 Identify different options of cancer therapy.  Most cancers are treated with a combination of approaches.

4.1b. Pre-contrast Axial T1 Wtd MRI4.1c. Post-contrast Axial T1 Wtd MRI4.1a. Axial T2 Wtd MRI 4.1d. Post-contrast Sagittal T1 Wtd MRI Patient with Intra-cranial.

A daganat-terápia alapjai Diagnosis –Histopathology –Tumor markers Cell surface markers (CD20, CD34…) Genetic markers (BRCA-1,Philadelphia chromosome)

Phase I Study of PLX4032: Proof of Concept for V600E BRAF Mutation as a Therapeutic Target in Human Cancer Flaherty K et al. American Society of Clinical.

LCC COL-1 See Pathologic Stage, Adjuvant Therapy, and Surveillance (LCC COL-3) Φ Φ Φ π π π Colon Cancer.

Supraclavicular metastasis from urothelial bladder carcinoma: A case report S. Farmahan, T. Mirza, P. Ameerally Oral Maxillofacial Department, Northampton.

Skin Cancer, Burns, and Tattoos. Skin cancer is the most common type of cancer 2 out of 5 cancers are skin cancers.

Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome WILLIAM M.

Comparison Between Definitive Chemoradiotherapy and Esophagectomy in Patients With Clinical Stage I Esophageal Squamous Cell Carcinoma Sachiko Yamamoto MD,

Results of Definitive Radiotherapy in Anal Canal Carcinoma

Fig. 8. Response to aromatase inhibitor and cyclin dependent kinase inhibitor in metastatic hormone receptor+, HER2 negative breast cancer. In this 29-year-old.

CT-guided 125I brachytherapy for mediastinal metastatic lymph nodes recurrence from esophageal carcinoma: Effectiveness and safety in 16 patients Fei.

Fig. 4. Follow-up abdominal computed tomography scans after six cycles of S-1/cisplatin combination chemotherapy (A, B) and 68 months after surgery (C,

Alvin Y. Liu, Martine P. Roudier, Lawrence D. True

Treatment With Continuous, Hyperfractionated, Accelerated Radiotherapy (CHART) For Non-Small Cell Lung Cancer (NSCLC): The Weston Park Hospital Experience.

Maria Belgun, L.Dumitriu, A.Goldstein, Mariana Purice, F.Alexiu

Percutaneous Cryoablation of Metastatic Ovarian Cancer for Local Tumor Control: Improved Patient Survival and Estimated Cost-Effectiveness Brandt P. Currier.

Histogenic analysis confirms prostate cancer metastasis to lung.

Figure 2 Response after initial increase in total tumour burden

Clonal evolution of resistance to sequential ALK inhibitor therapy.

Recent Advances in Bronchoscopic Treatment of Peripheral Lung Cancers

Intramedullary Spinal Cord Hemorrhage after Treatment with Bevacizumab in a Long- term Survivor with Metastatic Non–Small-Cell Lung Cancer Kristin N.

Volume 16, Issue 6, Pages (August 2016)

PET/CT Fusion Scan in Lung Cancer: Current Recommendations and Innovations Cristina Gámez, MD, PhD, Rafael Rosell, MD, PhD, Alejandro Fernández, MD, PhD,

Partial Response in an RRx-001-Primed Patient with Refractory Small-Cell Lung Cancer after a Third Introduction of Platinum Doublets Case Rep Oncol 2016;9:

Waging War on Cancer with the Sword of Immunity

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1–Negative Metastatic Squamous Cell Carcinoma of the Lung Zhigang.

Nat. Rev. Urol. doi: /nrurol

Papillary Thyroid Cancer Treated at the Mayo Clinic, 1946 Through 1970: Initial Manifestations, Pathologic Findings, Therapy, and Outcome WILLIAM M.

Prolonged Survival in a Case of Chemotherapy-Sensitive Gastric Cancer That Produced Alpha-Fetoprotein and Protein Induced by Vitamin K Antagonist-II Case.

Rapid Response of Brain Metastasis to Crizotinib in a Patient with ALK Rearrangement– Positive Non–Small-Cell Lung Cancer Hiroyasu Kaneda, MD, PhD, Isamu.

Osteoblastic Response in Patients with Non-small Cell Lung Cancer with Activating EGFR Mutations and Bone Metastases during Treatment with EGFR Kinase.

Tracheoesophageal Fistula Associated with Bevacizumab 21 Months after Completion of Radiation Therapy Elizabeth Gore, MD, Adam Currey, MD, Nicholas Choong,

Targeting T Cell Co-receptors for Cancer Therapy

Disease Flare After Treatment Discontinuation in a Patient With EML4-ALK Lung Cancer and Acquired Resistance to Crizotinib Oana Pop, MD, Augustin Pirvu,

Transformation to SCLC after Treatment with the ALK Inhibitor Alectinib Shiro Fujita, MD, PhD, Katsuhiro Masago, MD, PhD, Nobuyuki Katakami, MD, PhD,

Valerie W Rusch, MD, Ennapadam S Venkatraman, PhD

Computed tomographic images from a patient with BRAFL597S-mutant metastatic melanoma responding to therapy with the MEK inhibitor TAK-733. Computed tomographic.

European Urology Oncology

Clinical response to anti-ERBB3 mAb therapy in a patient with an advanced NRG1-rearranged non–small cell lung cancer. Clinical response to anti-ERBB3 mAb.

Combined BRAFi and anti-CTLA4 administration leads to prolonged antitumor immunity in a patient with metastatic melanoma. Combined BRAFi and anti-CTLA4.

PD-L1 expression by melanocytes is observed in geographic association with TILs but does not depend on BRAF V600E. PD-L1 expression by melanocytes is observed.

IL6 mRNA is not detected in metastatic prostate cancer cells.

AXL is not expressed in human prostate tumors.

Positive correlations between disease course and treatment-induced immune responses. Positive correlations between disease course and treatment-induced.

Serial imaging before and after immunotherapy among patients with MDM2/4 amplifications (N = 6). Serial imaging before and after immunotherapy among patients.

Imaging studies in patients attaining objective response on phase I study. Imaging studies in patients attaining objective response on phase I study. A,

In vivo bioluminescence imaging of primary tumors and tumor metastasis

A 63-year-old female with lung adenocarcinoma treated with nivolumab, who experienced pseudoprogression. A 63-year-old female with lung adenocarcinoma.

Molecular heterogeneity can drive mixed response and treatment failure in EGC. A, PET images from Patient #4 obtained before treatment and upon disease.

Correlation of PTEN loss in melanoma cells with an immune resistance phenotype. Correlation of PTEN loss in melanoma cells with an immune resistance phenotype.

Frequent coamplification of RTKs in MET-amplified EGC

Genomic determinants of response to cytotoxic chemotherapy.

Serial CT scan images from patient with a partial response.

Survival, subsequent therapies, and response.

SD-101 and low-dose radiation induces responses in patients with indolent lymphoma. SD-101 and low-dose radiation induces responses in patients with indolent.

SCLC PDX models recapitulate patient responses to an experimental therapy. SCLC PDX models recapitulate patient responses to an experimental therapy. A,

Evaluation of lymph node metastases in squamous cell carcinoma of the esophagus with positron emission tomography Kwhanmien Kim, MD, Seung Joon Park,

Single-site disease progression after 9 months of response to therapy in the right hemipelvis visualized by diffusion-weighted whole-body MRI. Top, fusion.

Figure 12a Pitfalls in N staging at CT and PET

Knockdown of ROR1 increases the invasive potential of melanoma cells in vitro and in vivo. Knockdown of ROR1 increases the invasive potential of melanoma.

Presentation transcript:

Clinical responses in patients. Clinical responses in patients. (A) Esophageal cancer patient E-1: large neck (top) and para-tracheal (bottom) lymph node metastases (yellow arrow) observed in CT images at 6 months after initiating treatment with the vaccine and a hemorrhagic protrusion in the esophagus (yellow arrow) observed by endoscopy at 3 months disappeared at 13 and 6 months, respectively. Only a scar was observed in the esophagus. Tumor recurrence was noted at 21 months and the patient died of disease progression at 23 months. Abbreviations: T, trachea; E, esophagus; V, vertebra. Esophageal cancer patient E-2: para-tracheal (top) and para-esophageal (middle) lymph node metastases (yellow arrow) observed at baseline in CT images disappeared by 3.5 months after initiating vaccine treatment. However, a metastatic tumor in the liver (bottom) (red arrow) grew rapidly and a new lesion was observed in a vertebra (bottom) (red arrow). Abbreviation: SGT, substituted gastric tube emplaced by surgical treatment. Esophageal cancer patient E-3: recurrence was observed after surgical treatment, radiation and chemotherapy. However, the tumor remained unusually stable for 7 months without any other treatment during vaccination. Esophageal cancer patient E-4: liver and multiple thoracic lymph node metastases were noted 4 months after esophagectomy. He was treated by chemotherapy, but showed no response. The patient was then treated with the vaccine, but no clinical response was observed. Abbreviations: ChT, chemotherapy; RT, radiation therapy; ST, surgical treatment. (B) PSA values were plotted over time for patients P-1, P-2, P-3 and P-4 who had recurrent hormone-refractory prostate cancer. Recurrence was defined as a continuous increase of PSA values at 3 consecutive time points at least 2 weeks apart. The PSA values of patients P-3 and P-4 showed no significant increase over a period of time during vaccination. The PSA values of patient P-2 also showed limited increase during vaccination. In malignant melanoma patient M-1, tumor infiltrates in the skin became surrounded by reddish areas associated with blistering at 10 days after the 2nd vaccination. Pictures at top left and right show the skin before and after blisters appeared, respectively. The blisters ruptured (bottom left) and recovered tumor cells were apoptotic as shown by HE staining (200x magnification) and annexin V staining (not shown). The patient died of rapid growth of metastatic tumors in the lung. Akiko Uenaka et al. Cancer Immun 2007;7:9 Copyright © 2007 by Eiichi Nakayama